TNFSF11 and neoplasm: Denosumab, a human monoclonal antibody that inhibits RANKL, is approved for the treatment of adults and skeletally mature adolescents with GCTB that is unresectable or when surgical resection is likely to result in severe morbidity.7, 8 Reductions in the tumor size and calcification of tumors have been observed after denosumab treatment, which may reduce blood loss and facilitate tumor resection and downgrade the operation.9